Bioequivalence and Bioavailability Forum

Main page Policy/Terms of Use Abbreviations Latest Posts

 Log in |  Register |  Search

Back to the forum  2018-06-19 01:14 CEST (UTC+2h)
MaggieSantos
Junior

Portugal,
2017-04-26 18:20

Posting: # 17271
Views: 1,386
 

 Narrow Therapeutic Index- valproic acid and derivatives [Regulatives / Guidelines]

Dear colleagues,

Concerning valproic acid and derivatives is not consentaneous that it should be considered as a narrow therapeutic índex for bioequivalence purposes. I know that for FDA it is a NTI. Do you have information for EMA, for individual European countries and for other countries around the World.

Depending on the submission country, the BE interval will differ.
Please, feel free to comment.

I need the more information I can get.

Kind Regards

MaggieSantos
DavidManteigas
Regular

Portugal,
2017-05-02 12:07

@ MaggieSantos
Posting: # 17290
Views: 1,044
 

 Narrow Therapeutic Index- valproic acid and derivatives

Hi MaggieSantos,

In the absence of a product specific guideline and a list of NTI drugs in Europe, I would opt for requesting scientific advise if your position is that valproic acid is not a nti drug.

Regards,
David
Back to the forum Activity
 Thread view
Bioequivalence and Bioavailability Forum |  Admin contact
18,384 posts in 3,905 threads, 1,172 registered users;
online 14 (1 registered, 13 guests [including 12 identified bots]).

You can’t fix by analysis
what you bungled by design.    Richard J. Light, Judith D. Singer, John B. Willett

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
HTML5 RSS Feed